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The host immune system functions constantly to
maintain chronic commensal and pathogenic organ-
isms in check. The consequences of these immune
responses on host physiology are as yet unexplored,
and may have long-term implications in health and
disease. We show that chronic viral infection in-
creases epithelial turnover in multiple tissues, and
the antiviral cytokines type I interferons (IFNs)
mediate this response. Using a murine model with
persistently elevated type I IFNs in the absence of
exogenous viral infection, the Irgm1/ mouse, we
demonstrate that type I IFNs act through nonepi-
thelial cells, including macrophages, to promote
increased epithelial turnover and wound repair.
Downstreamof type I IFN signaling, the highly related
IFN-stimulated genes Apolipoprotein L9a and b acti-
vate epithelial proliferation through ERK activation.
Our findings demonstrate that the host immune
response to chronic viral infection has systemic
effects on epithelial turnover through a myeloid-
epithelial circuit.
INTRODUCTION
Epithelial cells create lining and duct structures that are associ-
ated with many organs in the body (Blanpain et al., 2007). One
major function of these structures is to provide a first-line barrier
against the environment (Ashida et al., 2012). A central compo-
nent of this protection is cellular turnover, a highly regulated pro-
cess of shedding and regeneration of differentiated cells that at
the same time maintains barrier integrity. Loss of balance in this
process results in the eventual loss of barrier function. This
concept is most obvious in the intestine, which normally has a
high epithelial turnover rate (Kuhnert et al., 2004; Lee et al.,
2009). At homeostasis, each distinct epithelial structure has aCell Hdifferent rate of turnover, but the determinants of these unique
rates are poorly understood (Pellettieri and Sa´nchez Alvarado,
2007).
Turnover rates must also be capable of modulation in
response to injury so that wound repair can efficiently occur.
Damaged epithelial cells must be shed and rapidly replaced
with new cells generated by self-renewing stem cells (Blanpain
et al., 2007). Examples of damage that can alter turnover rates
include irradiation, malnutrition, and bacterial and parasitic
infection (Cliffe et al., 2005; Creamer, 1967; Luperchio and Scha-
uer, 2001; Rijke et al., 1975).
Themicrobiome of the host is a key component of the environ-
ment that is involved in homeostasis and injury response (Packey
and Ciorba, 2010; Pfefferle and Renz, 2014; Scales and Huffna-
gle, 2013). The virome is a relatively unexplored component of
the microbiome and is the complex collection of chronic viruses
within a given host (Virgin, 2014; Virgin et al., 2009). The role of
these chronic viral infections in epithelial cellular turnover has
not been previously addressed.
Type I interferons (IFNs) are a candidate for mediating sys-
temic alterations in response to viruses. They are a family of
innate immune cytokines that are produced as a result of viral
and other infections (Mu¨ller et al., 1994). They include multiple
IFNas, IFNb, and other subtypes (Pestka et al., 2004). Once
expressed and secreted from the cell, type I IFNs all bind to a
common type I IFN receptor, IFNAR, which is expressed on
most cell types (de Weerd et al., 2007). Despite sharing a
single receptor, type I IFNs can have different cellular effects
depending on the IFN subtype, the cell type, and the context
(i.e., additional cytokine signals) (Ivashkiv and Donlin, 2014;
Thomas et al., 2011). Upon ligand binding, Janus kinases that
are constitutively associated with IFNAR phosphorylate the
receptor and the signaling transducers and activators of tran-
scription (STATs) molecules (de Weerd et al., 2007). Upon phos-
phorylation, STATs form complexes that translocate to the
nucleus to induce the expression of hundreds of IFN-stimulated
genes (ISGs).
ISGs can be involved in a plethora of cellular processes
including apoptosis, transcriptional activation and repression,
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degradation, and posttranscriptional regulation of gene expres-
sion (de Veer et al., 2001). However, the functions of many ISGs
are yet to be discovered, as it is difficult to use viral infection
models to distinguish the effects of type I IFNs and ISGs on
host physiology from the effects of viral infection itself. To defin-
itively show that type I IFNs mediate an effect, loss-of-function
studies are required, but deficiency of type I IFNs during viral
infection typically results in unhindered viral replication, alter-
ations in the immune response, and significant morbidity and
mortality. For example, loss of type I IFN signaling during infec-
tion with murine homologs of ubiquitous chronic viruses such as
herpesvirus and cytomegalovirus (CMV) results in increased viral
titers and mortality (Barton et al., 2005; Chong et al., 1983; Dutia
et al., 1999). Here we used two in vivomodels to study the impact
of type I IFNs on host physiology: (i) the Irgm1/ mouse, which
we found has persistently elevated type I IFNs in the absence of
pathogenic viral infection, and (ii) injection of polyinosinic:
polycytidylic acid (polyI:C), a synthetic double-stranded RNA
that stimulates type I IFN induction. We showed that chronic viral
infection promoted epithelial turnover in multiple organs. We
then demonstrated that type I IFN signaling through macro-
phages promoted epithelial proliferation and enhanced injury
repair via the ISGs Apolipoprotein L9a and b.
RESULTS
Chronic Viral Infection Promoted Turnover of Multiple
Epithelial Organs
To test the role of chronic viral infection in the modulation of
epithelial turnover, we infected C57BL/6 wild-type (WT) mice
with murine CMV (MCMV), a DNA herpesvirus homologous to
highly prevalent human CMV (Virgin et al., 2009). Seven days
postinfection withMCMV (commencement of the chronic phase)
(Munks et al., 2006), we observed increased epithelial cell prolif-
eration and cell death within normally low-turnover organs (i.e.,
kidney, liver, salivary gland, and pancreas; Figures 1A–1C) (Pel-
lettieri and Sa´nchez Alvarado, 2007). The continued local pres-
ence of infectious virus was not required for increased turnover,
as only the salivary gland had detectable titers at this time,
consistent with the known kinetics of MCMV in C57BL/6 mice
(Figure S1A available online) (Munks et al., 2006; Sumaria
et al., 2009). A homolog of chronic human herpesvirus, murine
gammaherpesvirus 68 (MHV68; Virgin et al., 2009), also pro-
moted epithelial proliferation 16 days postinfection in the
absence of detectable titers in target tissues (Figures S1B and
S1C). At this time point, MHV68 is entering its chronic latent
phase (Tibbetts et al., 2003). However, in the small intestine,
we found that whileMCMV stimulated an increase in proliferation
(Figures 1D and 1E), infection with MHV68 or a persistent strain
of enteric murine norovirus (Nice et al., 2013) did not (Figures
S1D–S1G). These results suggested that certain chronic viral in-
fections can promote epithelial turnover in multiple organs.
Mice Deficient in Irgm1 Provided a Useful Model to
Study the Effects of Chronic Elevated Type I IFNs
We hypothesized that type I IFNs induced by viral infection stim-
ulated epithelial turnover. However, we could not test this hy-
pothesis in mice lacking the type I IFN response because these
cytokines are required for survival after infection with MCMV and86 Cell Host & Microbe 17, 85–97, January 14, 2015 ª2015 Elsevier IMHV68 (Barton et al., 2005; Chong et al., 1983; Dutia et al.,
1999). Therefore, we used a mouse model that we discovered
has chronic elevated type I IFN levels in the absence of infection,
the Irgm1/ mouse. Irgm1 is a p47 GTPase initially studied for
its role in host defense against intracellular protozoans and bac-
teria and in autophagy (Collazo et al., 2001; Feng et al., 2004; Liu
et al., 2013). Previous studies showed that Irgm1/ mice have
elevated serum type II IFN (IFNg) (King et al., 2011). However,
Irgm1/ mice bred in our enhanced barrier facility (Cadwell
et al., 2010) did not have detectable serum IFNg, and organ
levels of IFNg did not differ between WT and Irgm1/mice (Fig-
ure S2A). Instead, using a highly sensitive bioassay system
(Newby et al., 2007), we found that type I IFNs were elevated
in the serum of uninfected Irgm1/, but not Irgm1+/ mice.
Blocking antibodies specific for the type I IFN receptor chain IF-
NAR1 and a pan-anti-IFNa antibody effectively blocked the anti-
viral activity found in Irgm1/ serum (Figures 2A, 2B, and S2B–
S2D). Type I IFNs were elevated in Irgm1/mice from postnatal
day 7 to as late as 1 year (Figures S2E and S2F). The increased
type I IFNs were functional, as ISGs such as Oas2 and Mx2 were
elevated in numerous tissues of Irgm1/ mice (Figures 2C and
2D). The systemic elevation of type I IFNs in Irgm1/ mice has
not been previously reported, and provided us with a useful
model to study the role of these cytokines on host physiology.
Type I IFNs Promoted Epithelial Proliferation and
Turnover
To determine if type I IFNs increased epithelial turnover, we
compared WT, Irgm1/, and Irgm1/Ifnar/mice that lacked
responsiveness to type I IFNs, but retained elevated type I IFN
serum levels (Figure S3A). We found increased epithelial prolifer-
ation and cell death in the kidney, pancreas, liver, and salivary
gland of Irgm1/mice, but not Irgm1/Ifnar/mice compared
to WT mice (Figures 3A and 3B). The effects of type I IFNs were
not global, as proliferation levels in skeletal muscle, lung alveolar
cells, and thyroid gland epithelial cells in Irgm1/ mice were
similar to controls (Figure S3B).
We further examined the effect of type I IFNs on proliferation in
the intestine, where proliferation, cell death, and cell migration
occur in defined areas (Creamer, 1967; Potten, 1998). Irgm1/,
but not Irgm1/Ifnar/, intestines showed increased epithelial
proliferation compared to controls, as assessed by crypt height,
and BrdU incorporation and mitotic figure counts (Figures 3C–
3F). Increased proliferation was observed throughout Irgm1/
small intestinal crypts, including regions enriched for stem cells
(crypt base) and regions enriched for transit-amplifying cells
(upper crypt) (Figure S3C). As an additional control, we found
that intestinal epithelial proliferation in Ifnar/ mice was not
independently altered compared to WT controls (Figures 3D
and 3E).
Turnover in the small intestine takes place, in part, via cell
migration from the base of crypts that culminates with apoptosis
and shedding of differentiated cells at the tips of villi (Creamer,
1967). Using a double-thymidine analog-labelingmethod (Maho-
ney et al., 2008), we found that epithelial cells migrated faster in
Irgm1/ mice compared to WT or Irgm1/Ifnar/ mice (Fig-
ures 3G and S3D). Notably, no excess cell death of progenitor
intestinal epithelial cells occurred in Irgm1/mouse crypts (Fig-
ure S3E). In addition, recombinant murine IFNaA did not directlync.
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Figure 1. MCMV Infection Promoted Epithelial Turnover in Multiple Organs
(A) Representative immunohistochemistry for Ki67 in kidney, liver, salivary gland (SG), and exocrine pancreas of mock-infectedmice or mice infected with 53104
pfu MCMV (Smith strain), 7 days (d7) after i.p. infection. Blue bars, 100 mm; red bars, 50 mm. Black boxes indicate insets (right-most column). Black arrowheads
show examples of enumerated Ki67+ epithelial cells.
(B and C) Graph of the average number ± SEM of (B) Ki67+ epithelial cells per high-power field (hpf; 4003) and (C) TUNEL+ bodies/hpf relative to mock-infected
animals.For (B), approximately25hpfswerequantifiedperorgan,andonlyepithelial cellswerecounted,and for (C), approximately50hpfsperorganwerequantified.
(D and E) Graph of (D) average crypt height and (E) average number of mitotic figures ± SEM of 100 crypts in mock- and MCMV-infected mice. Lengths of crypts
were measured from histological slides using ImageJ software. Mitotic figures were countedmanually. For (B)–(E), mock-infected n = 6mice, MCMV-infected n =
5 mice from two independent experiments (ind. expts.). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Student’s t test for each organ. See also Figure S1.
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Figure 2. Irgm1–/– Mice Had Elevated Functional Circulating Type I IFNs
(A) Graph of IFN activity measured in serum using a bioassay system (described in Figure S2C). IFN activity was calculated using a standard curve from
recombinant murine IFNaA run concomitantly with assay samples. WT n = 22 mice, Irgm1/ n = 28 mice from five individual experiments.
(B) Bars show antiviral activity of WT and Irgm1/ serum after administration of anti-Ifnar1, anti-pan-IFNa, and anti-IFNb1 antibodies during the serum bioassay.
WT n = 4 mice, Irgm1/ n = 6 mice.
(C and D) Graphs of mean fold change ± SEM of (C) Oas2 and (D) Mx2 mRNA in Irgm1/ tissues compared to WT tissues. n = 2–9 mice per genotype per organ.
*p < 0.05, **p < 0.01, ****p < 0.0001 by Student’s t test. See also Figure S2.induce cell death in primary intestinal epithelial progenitor cells
(Miyoshi et al., 2012; Miyoshi and Stappenbeck, 2013) derived
from WT, Ifnar/, and Irgm1/ mice, despite the capacity of
these cells to respond to type I IFNs by increasing ISG expres-
sion (Figures S3F and S3G). These results suggested that type
I IFNs did not directly induce cell death in epithelial progenitor
cells. However, it is likely that turnover-associated death of
differentiated cells at villus tips was accelerated.
Elevated Type I IFNs in Irgm1–/– Mice Enhanced Wound
Healing
To gauge the physiologic importance of type I IFN-driven epithe-
lial turnover, we evaluated wound repair. We first administered
diclofenac, a nonsteroidal anti-inflammatory drug (NSAID),
which induces small intestinal ulcerations within 24 hr after a
single i.p. dose of 60 mg/kg (Ramirez-Alcantara et al., 2009).
While ulcers were formed in all mice after 18 hr, Irgm1/ mice
had fewer detectable intestinal ulcers compared to WT and
Irgm1/Ifnar/ mice at days 2 and 4 postinjection (Figures
4A, 4B, and S4A), indicating that Irgm1/ mice healed ulcera-
tions more rapidly than controls. We also investigated colonic
repair using a biopsy injury model (Seno et al., 2009). In this
model, wound-associated epithelial (WAE) cells migrate over
the wound bed surface to cover the injury. The source of WAE
cells are wound-adjacent crypts, and decreased epithelial cell
proliferation in these crypts is associated with slowed and
incomplete wound healing (Miyoshi et al., 2012; Seno et al.,
2009). We observed a greater distance covered by WAE cells
at day 4 postinjury in wounds of Irgm1/ mice that correlated
with the percentage of proliferating cells in wound-adjacent88 Cell Host & Microbe 17, 85–97, January 14, 2015 ª2015 Elsevier Icrypts (Figures 4C, 4D, and S4B). Taken together, these findings
demonstrated that elevated epithelial proliferation in response to
type I IFNs enhanced healing after epithelial damage.
Type I IFNs Signaled through Macrophages to Promote
Epithelial Proliferation
We further extended our findings by using an additional model of
type I IFN production: injection of polyI:C, a synthetic dsRNA
(Figures S5A and S5B). Daily low-dose polyI:C injection for
4 days stimulated type I IFN production and increased epithelial
proliferation in WT, but not Ifnar/, mice (Figures 5A–5F, S5A,
and S5B). These data demonstrated that exogenous type I
IFNs can increase epithelial proliferation.
We next tested whether type I IFNs act directly on the epithe-
lium to promote proliferation by crossing Irgm1/ mice with
mice lacking Ifnar solely in the intestinal epithelium (Irgm1/
Ifnarf/f-Villin-Cre; Irgm1/ IfnarVC mice; Figure S5C; el Marjou
et al., 2004). Irgm1/IfnarVCmice had elevated levels of serum
type I IFNs and increased intestinal epithelial proliferation com-
parable to Irgm1/mice (Figures 5G and S3A). This finding sug-
gested that nonepithelial cell type(s) must be responding to type I
IFNs to stimulate epithelial cell proliferation. We verified this
finding in vitro: addition of IFNa did not directly affect prolifera-
tion of primary intestinal epithelial cells (Figure S5D).
Next, to identify the cell type required for epithelial hyperprolif-
eration in response to type I IFN, we assessed the effects of
polyI:C injection in mice deficient in Ifnar expression in different
cell types. PolyI:C treatment of IfnarVCmice showed augmented
intestinal epithelial turnover (Figures S5E and S5F). However,
polyI:C treatment of mice lacking Ifnar on macrophages andnc.
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Figure 3. Elevated Type I IFNs in Irgm1–/– Mice Promoted Enhanced Epithelial Turnover
(A) Quantification of the average number of Ki67+ cells/hpf ± SEM n = 6–11 mice per genotype.
(B) Quantification of average number of TUNEL+ bodies per hpf ± SEM n = 5–10 mice per genotype. For (A) and (B), approximately 50 hpfs were examined per
organ. For each organ, means with different letters are significantly different (p < 0.05) by Tukey’s multiple comparisons test.
(C) Representative histology of small intestinal crypts of WT, Irgm1/, and Irgm1/Ifnar/mice. Red bar, 50 mm. Yellow bars delineate the height of a crypt; red
arrowheads mark mitotic figures.
(D and E) Graph of (D) average crypt height and (E) average number of mitotic figures (MF) ± SEM of 100 crypts in WT (n = 23 mice), Irgm1/ (n = 18 mice),
Irgm1/Ifnar/ (n = 18 mice), and Ifnar/ (n = 10 mice) compiled from four ind. expts. Bars with different letters have significantly different means (p < 0.05) by
Tukey’s multiple comparisons test.
(F) Quantification of the average number ± SEM of BrdU+ cells per crypt. Mice were injected with BrdU 1 hr before sacrifice. The number of immunofluorescently
stained BrdU+ cells was counted over an average of 50 crypts. WT n = 3 mice, Irgm1/ n = 3 mice, Irgm1/Ifnar/ n = 2 mice.
(G) Graph of the average migration rate ± SEM of small intestinal epithelial cells calculated relative to WT controls. n = 100 villi/mouse evaluated in two-color
thymidine analog experiments.WT n = 11mice, Irgm1/ n = 17mice, Irgm1/Ifnar/ n = 9mice from four ind. expts. For (F) and (G), **p < 0.01, ****p < 0.0001 by
Tukey’s multiple comparisons test. See also Figure S3.granulocytes (Ifnarf/f-LysM-Cre; IfnarLysMmice;Prinz et al., 2008)
did not induce epithelial proliferation to the same extent as con-
trols (Figure 5H), even though type I IFN levels were induced at
similar levels (Figure S5G). Endogenous LysM is highly expressedCell Hon both neutrophils and macrophages (Cross et al., 1988). How-
ever, neutrophil depletiondidnotdiminishepithelial hyperprolifer-
ation induced by polyI:C injection, consistent with macrophages
mediating this effect (Figures 5I, S5H, and S5I).ost & Microbe 17, 85–97, January 14, 2015 ª2015 Elsevier Inc. 89
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Figure 4. Irgm1–/– Mice Had Accelerated
Wound Healing Due to Type I IFNs
(A) Graph of the average number ± SEM of ulcers
per small intestine 18 hr, 2 days (D2), and 4 days
(D4) after i.p. injection of 60 mg/kg diclofenac so-
dium salt in sterile PBS. n = 3–8mice per genotype
per day, from five ind. expts. *p < 0.05 by Tukey’s
multiple comparisons test.
(B) Representative whole mount images of
formalin-fixed small intestinal wounds of WT,
Irgm1/, and Irgm1/Ifnar/ mice 4 days after
diclofenac injection. Dotted black lines outline the
wound. All images at 323.
(C) Graph of the average distance covered by
WAE cells 4 days after colonic biopsy wounding.
Quantification was performed blinded on whole
mount images of formalin-fixed wounds using
ImageJ software. Ten measurements per wound
were averaged. WT n = 8 wounds in 4 mice,
Irgm1/ n = 12 wounds in 4 mice, Irgm1/
Ifnar/ n = 9 wounds in 3 mice.
(D) Representative whole mount images at 903
magnification of colonic biopsy wounds 4 days
after wounding. Black arrows delineate the dis-
tance migrated by WAE cells. See also Figure S4.The ISGs Apol9a/b Were Candidate Factors to Mediate
Proliferation in Irgm1–/– Mice
We next determined the factors downstream of IFN signaling
that augmented epithelial turnover. Serum from Irgm1/, WT,
polyI:C-treated, and saline-treated mice showed no elevation
in several established pro-proliferative factors (Figures S6A
and S6B). We therefore performed microarray analysis of whole
genome RNA of salivary gland, small intestine, and isolated
colonic macrophages from Irgm1/ and WT mice (Figure S6C).
Apol9a and Apol9b, highly homologous apolipoproteins (98% by
nBLAST analysis), were two factors with enhanced gene expres-
sion in Irgm1/ mice that were also potentially secreted (Fig-
ure S6C; Table S1). These apolipoproteins are ISGs (Rusinova
et al., 2013); however, their exact function is unknown. We veri-
fied enriched gene expression of Apol9a/b in Irgm1/ mice
using qRT-PCR (Figure 6A). Apol9a/b gene expression was
also elevated in MCMV-infected tissues compared to mock-
infected animals (Figure 6B). In situ hybridization for Apol9a
showed expression in discrete foci within the salivary gland
and small intestine in Irgm1/mice (Figures 6C and 6D). Within
these foci, most cells were positive for Apol9a, including macro-
phages (Figure S6D), other stromal cells, and epithelial cells
themselves (Figures 6C and 6D, insets).
Apolipoprotein L9 Promoted Epithelial Proliferation
through ERK Activation
Notably, the focal pattern of Apol9a gene expression within the
salivary gland was associated with areas of high epithelial prolif-
eration (Figure S7A). To determine whether Apol9a could pro-
mote proliferation, we used a bioluminescence-based assay to
quantify proliferation of Apol9a-expressing epithelial cells. This
method utilized knock-in mice expressing a fusion protein be-
tween Cdc25A and click beetle red luciferase (CBRLuc) in the
endogenous Cdc25a locus (Figures 7A–7C). Cdc25A is a cell
cycle phosphatase with peak protein levels during mitosis
(Boutros et al., 2006). Luminescence from Cdc25A-CBRLuc-90 Cell Host & Microbe 17, 85–97, January 14, 2015 ª2015 Elsevier Iexpressing cells upon addition of D-luciferin substrate thus
provided a direct readout of mitotic activity. Imaging of
Cdc25A-CBRLuc colonic epithelial spheroid cultures revealed
an increase in luminescence over a 48 hr culture period (Figures
7C and S7B), which correlated with the number of viable cells
(Figure S7C).
We assessed luminescence levels of Cdc25A-CBRLuc intesti-
nal epithelial cells expressing either Apol9a, a positive control
R-spondin3 (Rspo3), or a negative control construct for 24 hr
(Figures 7D and S7B). R-spondins enhanceWnt signaling to pro-
mote proliferation and survival of tissue stem cells (Haegebarth
and Clevers, 2009). Both Rspo3 and Wnt3a are required in the
normal growth media for primary intestinal epithelial spheroids
(Miyoshi et al., 2012; Miyoshi and Stappenbeck, 2013). Under
these conditions, small intestinal epithelial cells expressing
Apol9a and the positive control Rspo3 had greater proliferation
compared to control cells (Figure 7D). However, in media with
Wnt3a alone, only epithelial cells expressing Rspo3 were able
to proliferate, suggesting that Apol9a cannot substitute for
Rspo3 to augment Wnt signaling (Figure 7E). Indeed, no signifi-
cant enhancement of Wnt signaling was observed in vivo in
Irgm1/ mice (Figures S7D and S7E). Similar results were ob-
tained in WT cells expressing Apol9a and Rspo3 using an EdU
incorporation assay (Figure S7F). These results suggested that
Apol9a expression within epithelial cells was able to stimulate
epithelial proliferation.
Next, to discover potential pathways downstream of Apol9a
expression, we analyzed cell lysates of control, Rspo3-, and
Apol9a-expressing intestinal epithelial cells using a phosphoki-
nase dot blot array. Apol9a-expressing epithelial cells showed
elevations in phospho-ERK1/2 compared to control cells (Fig-
ure S7G), which we verified by immunoblotting (Figure 7F).
ERK kinases are the downstream signaling component of the
MAPK pathway, and have been implicated in promoting cell
cycle progression and proliferation (Rubinfeld and Seger,
2005). Addition of the MEK inhibitor U0126 inhibited ERK1/2nc.
phosphorylation and reduced proliferation of Apol9a-expressing
intestinal epithelial cells, as well as control cells, in a dose-
dependent manner (Figures 7G, S7H, and S7I). These findings
implicated activation of the ERK pathway, which was important
for epithelial cell proliferation, downstreamof Apol9a expression.
Macrophages Expressing Apol9a Were Able to Promote
Epithelial Proliferation in trans
Finally, we investigated the role of type I IFN signaling in macro-
phages on Apol9a-mediated epithelial proliferation. Based on
the localization of Apol9a on macrophages by in situ hybridiza-
tion (Figure S6D), we determined whether type I IFN signaling
could induce Apol9a/b in macrophages and stimulate prolifera-
tion in trans. First, we found that Apol9a/b expression was
induced by IFNa in WT, but not Ifnar/, macrophages (Fig-
ure S7J). We then transfected 293FT cells with FLAG-tagged
Apol9a and detected FLAG-tagged Apol9a protein within the
supernatant, suggesting that Apol9a can be secreted (Fig-
ure S7K). Next, we expressed Apol9a or a control construct in
WT bone marrow-derived macrophages and cocultured these
cells with Cdc25A-CBRLuc intestinal epithelial cells. Macro-
phages expressing Apol9a enhanced proliferation of epithelial
cells greater than control macrophages or epithelial cultures
alone (Figure 7H). These results suggested that macrophages
promoted epithelial proliferation in trans via Apol9a expression.
DISCUSSION
Taken together, these findings uncover a pathway linking viral
infection with enhanced epithelial turnover via type I IFNs. Spe-
cifically, we showed that elevated type I IFNs can signal through
macrophages to enhance epithelial proliferation and injury
repair. We demonstrated that the highly related ISGs Apol9a/b
promoted epithelial proliferation. These results redefine the cur-
rent view of type I IFN effects on proliferation in vivo and enhance
our understanding of conditions with elevations in these cyto-
kines, such as viral infection and autoimmunity.
The indirect effect on epithelial proliferation driven by viral
infection has not been previously described. The viruses that
stimulated epithelial proliferation are murine homologs of highly
prevalent human chronic viruses, CMV and herpesvirus, both
systemic DNA viruses (Virgin et al., 2009). In contrast, murine
norovirus, an RNA virus, did not stimulate proliferation in the in-
testine, where it is tropic (Nice et al., 2013). These results suggest
that not all viruses can stimulate enhanced epithelial prolifera-
tion, perhaps due to differences in tissue tropism, viral patho-
genesis, and/or virus-encoded proteins. In humans, host factors
may also play a role in the extent of induced proliferation, as ge-
netic differences can affect immune responses to pathogens,
including the type I IFN response (Lee et al., 2014). Since chronic
viral infection clearly has a systemic effect on host physiology,
and all individuals possess a collection of persistent viruses as
their virome, the use of mouse models with chronic viral infec-
tions may uncover new biology.
We found that the effects of type I IFNs on epithelial prolifera-
tion are indirect through an additional cell type that includes
macrophages. We propose that macrophages can act as a relay.
Because of their widespread distribution, these cells are poised
to synthesize information frommultiple local and remote sourcesCell Hand then in turn instruct proximal epithelial cells. The use of an
integrative relay enables the separation of signal from noise
and allows for the amplification of additive weak signals. The
pattern of foci of Apol9a expression observed in the salivary
gland and small intestine supports the concept of a central cell
that spreads and amplifies signals to neighboring cells. Our
data suggest a model in which type I IFNs signal on macro-
phages to promote expression of Apol9a/b, which can stimulate
proliferation in nearby epithelial cells. One possibility is that
Apol9a/b is secreted from macrophages and then stimulates
its own expression in epithelial cells, where it activates ERK to
promote cell cycle progression. It is also possible that other
ISGs expressed in macrophages can promote Apol9a/b expres-
sion in epithelial cells as well. Our work extends a proposed role
for macrophages in epithelial maintenance and repair by impli-
cating type I IFNs in this pathway (Farache et al., 2013). This
myeloid-epithelial circuit could be used by other cytokine
signaling systems to modulate diverse epithelial functions.
We propose that Apol9a/b is one of the mediators of the type I
IFN response directed toward epithelial progenitors. Relatively
little is known about the ApoL family. In humans, there are six
known ApoLs, five of which are thought to be IFN stimulated (Ru-
sinova et al., 2013; Smith and Malik, 2009). In mice, there are as
many as 14 apolipoprotein L members (Vanhollebeke and Pays,
2006). In contrast to other apolipoprotein families, only APOL1
has been implicated in lipid transport andmetabolism to date (Al-
bert et al., 2005; Duchateau et al., 2000). Interestingly, increased
expression of ApoLs has been observed in cervical and breast
cancer (Ahn et al., 2004; Jung et al., 2005). Apol9b has been
implicated in antiviral protection in L929 cells and primary neu-
rons, but the extent and mechanism of such protection was un-
clear (Kreit et al., 2014). In this report, we show that Apol9a can
be secreted and promotes epithelial proliferation. Since there are
hundreds of ISGs that can be induced in a given cell type, it is
unlikely that Apol9a and b are the sole mediators of type I IFN-
dependent epithelial proliferation. Other ISGs may have redun-
dant functions. Nonetheless, Apol9a/b and the ApoL family are
ISGs that warrant further study in the context of homeostasis
and during viral infection.
We show that Apol9a expression can enhance activation of
the ERK pathway and in turn proliferation. The connection be-
tween the ERK pathway and proliferation is well supported by
previous studies, which show that ERK activation promotes
cell cycle progression and cellular differentiation (Rubinfeld
and Seger, 2005; Zhang and Liu, 2002). Sustained ERK activa-
tion activates cyclin D1 expression and decreases CDK inhibitor
levels to allow cells to pass the G1 restriction point and enter the
S phase of the cell cycle (Rubinfeld and Seger, 2005). Thus, an
increase in ERK activation would be able to increase the rate
of cell cycling.
Modulation of the ERK pathway would allow for an additional
level of control of proliferation in epithelial organs beyond Wnt
signaling, which is required for themaintenance of stem and pro-
genitor cells (Haegebarth and Clevers, 2009; Reya and Clevers,
2005). Wnt ligands bind to their receptor complex and trigger the
localization of b-catenin to the nucleus, where it associates with
transcription factors that activate multiple target genes to pro-
mote a baseline rate of self-renewal and proliferation (Reya
and Clevers, 2005). The source of Wnts is thought to be localost & Microbe 17, 85–97, January 14, 2015 ª2015 Elsevier Inc. 91
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Figure 5. Type I IFNs Signaled through Macrophages to Indirectly Promote Epithelial Turnover
(A and B) Graph of (A) the average crypt height and (B) average number ofMF/100 crypts ± SEM inWT and Ifnar/mice injected i.p. with saline or 5mg/kg polyI:C
for 4 days. WT n = 13 mice for each treatment; Ifnar/ n = 5 mice for each treatment.
(C–F) Graphs of the average number of Ki67+ cells/hpf ± SEM relative to saline-treatedmice in submandibular salivary gland, exocrine pancreas, liver, and kidney.
WT n = 7–8 mice each treatment; Ifnar/ n = 3 mice each treatment. For (A)–(F), orange bars represent saline-treated mice and purple bars represent polyI:C-
treated mice. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Tukey’s multiple comparisons test.
(G) Graph of the average crypt height and the average number of MF of 100 crypts ± SEM in control (n = 9 mice), Irgm1/ (n = 8 mice), Irgm1/IfnarVC (n = 7
mice), and IfnarVC (n = 6 mice). Control mice were Irgm1+/+Ifnarf/f-VillinCre negative. Means with different letters are significantly different by Tukey’s multiple
comparisons test.
(legend continued on next page)
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Figure 6. The ISGs Apol9a and Apol9bWere
Elevated in Stromal and Epithelial Cells of
Irgm1–/– and MCMV-Infected Mice
(A) Quantification of the average expression ±SEM
of Apol9a/b mRNA in Irgm1/ small intestine,
salivary gland, and isolated colonic macrophages
relative to WT tissue as measured by qRT-PCR.
n = 3mice per genotype. Primers were designed to
amplify both Apol9a and b. *p < 0.05 by Student’s
t test for each organ.
(B) Quantification of the average expression ±
SEM of Apol9a/b mRNA in MCMV-infected sali-
vary gland, liver, and kidney relative to mock-
infected tissue as measured by qRT-PCR. Mock-
infected n = 3 mice; MCMV-infected n = 5 mice.
***p < 0.001 by Student’s t test for each organ.
(C and D) Representative in situ hybridization im-
ages for Apol9a in WT and Irgm1/ (C) salivary
gland and (D) small intestine. Apol9a expression is
indicated by dark purple staining. Lower images
are insets of upper images showing foci of Apol9a
expression. The black arrowhead indicates an
Apol9a-positive stromal cell, and dashed black
lines outline an Apol9a-positive epithelial gland.
Blue bar, 200 mm; red bar, 100 mm. See also
Figure S6.nonepithelial mesenchymal cells and, in the intestine, also
Paneth cells (Farin et al., 2012). In contrast, type I IFN signaling
can generate a signal at the systemic level. Downstream activa-(H) Graph of the average crypt height and average number of MF/100 crypts ± SEM in control and IfnarLysMm
saline n = 9 mice; polyI:C n = 11 mice. IfnarLysM: saline n = 7 mice; polyI:C n = 8 mice. Control mice were Ifna
ind. expts.
(I) Graph of the average crypt height and average number of MF/100 crypts ± SEM inWTmice treated with isot
anti-Ly6G (saline n = 6 mice; polyI:C n = 6 mice). Results compiled from two ind. expts. For (H) and (I), the a
shown. *p < 0.05, ****p < 0.0001 by Student’s t test. See also Figure S5.
Cell Host & Microbe 17, 85–9tion of the ERK pathway could then in-
crease the normal rate of cell cycling in
stem and progenitor cells. We propose
that type I IFNs provide additional sys-
temic control of epithelial proliferation
and healing under nonhomeostatic con-
ditions of infection and injury.
Finally, many human conditions are
associated with elevated type I IFN signa-
tures, similar to our observations in the
Irgm1/ mouse. For example, upregula-
tion of type I IFNs is associated with the
type I interferonopathies, a group of Men-
delian disorders (Crow, 2011; Rice et al.,
2014), as well as systemic lupus erythe-
matosus (SLE) (Di Domizio and Cao,
2013). These diseases, which include
Aicardi-Goutieres syndrome (AGS) and
spondyloenchondrodysplasia (SPENCD)
are proposed to arise from either (i) inap-
propriate activation of the type I IFN
response or (ii) inadequate negative regu-
lation of type I IFN production (Crow,
2011). While the molecular bases ofsome cases of type I interferonopathy are known, many cases
remain genetically uncharacterized. It would be interesting to
determine whether there are gene changes in human IRGM inice injected i.p. 5mg/kg polyI:C for 4 days. Control:
rf/f-LysMCre negative. Results compiled from three
ype control (saline n = 5mice; polyI:C n = 6mice) or
verages ± SEM relative to saline-treated mice are
7, January 14, 2015 ª2015 Elsevier Inc. 93
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Figure 7. Apol9a Augmented Epithelial Pro-
liferation through ERK1/2 Activation
(A) Schematic representation of Cdc25A-CBRLuc
fusion protein expressed in the endogenous
Cdc25A locus.
(B) Gray scale photograph and bioluminescence
image of gastrointestinal tract of WT mice (A/A)
and knock-in mice heterozygous (A/Luc) for the
Cdc25A-CBRLuc fusion protein. Mice were in-
jected i.p. with D-luciferin, sacrificed, and the
labeled organs were subjected to biolumines-
cence imaging ex vivo. Photon flux is indicated by
the pseudocolored heatmap.
(C) Bioluminescence image of Cdc25A-CBRLuc-
expressing colonic epithelial cell growth over time.
Colonic epithelial spheroid cultures were estab-
lished from homozygous (ALuc/ALuc) knock-in
mice. D-luciferin was added (t = 0 hr), and biolu-
minescence was measured, and fresh media with
D-luciferin replaced at 24 hr.
(D and E) Graph of the fold change in lumines-
cence during a 24 hr period after addition of
D-luciferin in Cdc25A-CBRLuc intestinal spheroid
cultures cultured with (D) media containing Rspo3
and Wnt3a or (E) Wnt3a only. Cells express
Rspo3, Apol9a, or a negative control. The
average fold change in luminescence relative to
luminescence measured at 4 hr, ± SEM, after
background subtraction, of three ind. expts. are
shown, with 12–18 replicates per cell line per
experiment. (D) p = 0.0389 and (E) p = 0.0574 by
repeated-measures two-way ANOVA. Asterisks
indicate **p < 0.01 and ****p < 0.0001 at 24 hr
only by Dunnett’s multiple comparisons test with
comparison to control cells.
(F) Western blot of phosphorylated and total
ERK1/2 (p42 and p44) of cells expressing a
negative control, Rspo3, or Apol9a. Background-
subtracted representative image from three ind.
expts. is shown.
(G) Graph of the fold change in luminescence
measured during a 24 hr period after addition of
D-luciferin and differing concentrations of MEK
inhibitor U0126 in Apol9a-expressing Cdc25A-
CBRLuc intestinal spheroid cultures. The average
fold change in luminescence relative to lumines-
cence measured at 4 hr, ± SEM, of two ind. expts.
is shown, with three replicates per dose per
experiment. p = 0.0066 by repeated-measures
two-way ANOVA for 10 mm U0126.
(H) Graph of the fold change in luminescence
measured during a 28 hr period after addition
of D-luciferin of Cdc25A-CBRLuc intestinal
spheroid cultures cultured with WT macrophages
expressing Apol9a or a control construct, or
without macrophages. The average fold change
in luminescence relative to luminescence measured at 4 hr, ± SEM, of three ind. expts. is shown, with 4–5 technical replicates per experiment. p = 0.0297 by
repeated-measures two-way ANOVA. *p < 0.05, ***p < 0.001 at 24 hr only by Sidak’s multiple comparisons test. See also Figure S7.these cases that are linked with elevated type I IFN. In addition,
we have only limited understanding of the role of type I IFNs on
disease pathogenesis and progression. Our findings here sug-
gest that elevated type I IFNs may not be sufficient to cause
the severe autoimmunity seen in SLE, AGS, and SPENCD. We
did not observe the abnormal skin, brain, or bone dysplasias
typically seen in these conditions in Irgm1-deficient mice (data94 Cell Host & Microbe 17, 85–97, January 14, 2015 ª2015 Elsevier Inot shown). Instead, we observed increased epithelial turnover,
with both augmented cell proliferation and cell death. It is
possible that this elevated turnover could increase the risk for
exposure of cell contents, such as nucleic acids, to the immune
system. Additional genetic or environmental contributions could
then trigger autoimmunity to the cellular components. Our find-
ings show that constitutively elevated type I IFNs can promotenc.
systemic epithelial proliferation and cell death, thus expanding
our knowledge of the host response during infection and
autoimmunity.
EXPERIMENTAL PROCEDURES
Mice
All experimental procedures were performed under approval by Washington
University’s Animal Studies Committee. For experimentswith knockoutmouse
lines, heterozygote breeding pairs were used to obtainWT controls. For exper-
iments using lineage-specific knockouts, heterozygous crosses were used to
generate Cre-negative controls. Cdc25A-CBRLuc reporter mice were gener-
ated on a B6(Cg)-Tyrc-2J/J (B6-albino) background. A targeting construct con-
taining DNA encoding a fusion protein of Cdc25A and CBRLuc was knocked in
to the Cdc25A locus by homologous recombination.
In Vivo Treatment of Mice
For MCMV infection, 6- to 8-week-old male and female mice were injected
i.p. with 53104 plaque-forming units (pfu) MCMV Smith strain (salivary gland
derived). Mice were sacrificed 7 days postinfection. For MHV68 infection, 6-
to 8-week-old male and female mice were injected i.p. with 13106 pfu virus.
Mice were sacrificed 7 days postinfection. Titer determinations for both
MCMV and MHV68 were performed on NIH 3T12 fibroblasts with methylcellu-
lose overlay as previously described (Canny et al., 2014). The limit of detection
of the MCMV plaque assays was 40 pfu/organ, while the limit of detection of
the MHV68 assay was 100 pfu/organ. For polyI:C experiments, 5 mg/kg
polyI:C (GE Healthcare Life Sciences) diluted in sterile saline or saline alone
was injected i.p. once every 24 hr for 4 days. Mice were sacrificed on day 5.
For neutrophil-depletion experiments, 500 mg/mouse of monoclonal anti-
Ly6G antibody (BioXCell) or rat IgG2a isotype control (BioXCell) diluted in
250 ml sterile saline was injected i.p. 1 day prior and 2 days following the onset
of polyI:C injections.
Type I IFN Bioassay
Type I IFNbioassaywasperformedaspreviouslydescribed (Newbyet al., 2007),
with further details provided in the Supplemental Experimental Procedures.
Tissue Histology and Immunohistochemistry
Detailed methods are described in Supplemental Experimental Procedures.
Epithelial mitotic figures were quantified from H&E-stained sections of Bouin’s
fixed small intestines. Crypt depth was measured from the same sections by
ImageJ software. All slides were blinded prior to quantification.
Primary Intestinal Spheroid Epithelial Culture
Colonic and small intestinal crypts were isolated from mice and cultured in a
3D Matrigel as previously described (Miyoshi et al., 2012; Miyoshi and Stap-
penbeck, 2013).
Bioluminescence Imaging of Whole Organs and Intestinal Epithelial
Spheroids
Detailed methods are further described in Supplemental Experimental Proce-
dures. Colonic crypts were isolated from knock-in mice that were homozygous
(ALuc/ALuc) for the Cdc25A-CBRLuc fusion protein, and intestinal spheroids
were cultured in conditionedmedia as described above. For luminescence ex-
periments with lentivirus construct-expressing cells, spheroids were trypsi-
nized and seeded onto 96-well plates. Media containing 200 mg/ml D-luciferin
(Biosynth) was added to each well, and cells were imaged at 37C in an
EnVision Multilabel Plate Reader (PerkinElmer) with a 1 s exposure per well.
Luminescence was measured every 4 hr for 24 hr, and the fold change in lumi-
nescence relative to luminescence measured at 4 hr was plotted. This time
point was chosen because the measurements at t0 are close to background,
as it takes some time after the addition of D-luciferin for this substrate to be
metabolized by the luciferase.
Statistics
GraphPad Prism software (version 6) was used to perform all statistical ana-
lyses unless otherwise specified.Cell HACCESSION NUMBERS
The Gene Expression Omnibus (GEO) accession number for the microarray
data reported in this paper is GSE59603.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.chom.2014.11.004.
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